SCHEMBL22505271

SCHEMBL22505271

C/C=C1\N=C(c2ccc(C)s2)OC1=O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 5/20 0.40
RAB9A P51151 5/20 0.40
PGR P06401 1/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
MAPK1 P28482 2/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
NOTUM Q6P988 4/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 3/20 0.36
TP53 P04637 1/20 0.35
F2 P00734 1/20 0.35
THRB P10828 1/20 0.34
RECQL P46063 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24241532 0.83 MAPT (0.49) KDM4ENPC1RAB9ASMN1; SMN2MAPK1
SCHEMBL24534969 0.79 KMT2A (0.65) KDM4EMAPK1KMT2AMEN1NOTUM
SCHEMBL6875359 0.79 KMT2A (0.65) KDM4EMAPK1KMT2AMEN1NOTUM
SCHEMBL24534938 0.79 KDM4E (0.39) KDM4ENPC1RAB9APGRSMN1; SMN2
SCHEMBL24534751 0.77 KDM4E (0.71) KDM4ENPC1RAB9APGRSMN1; SMN2
SCHEMBL24534491 0.77 PGR (0.38) KDM4ENPC1RAB9APGRSMN1; SMN2
SCHEMBL13205734 0.77 MAPK1 (0.66) KDM4ERAB9ASMN1; SMN2MAPK1NOTUM
SCHEMBL15512480 0.77 MAPK1 (0.66) KDM4ERAB9ASMN1; SMN2MAPK1NOTUM
SCHEMBL15512479 0.77 MAPK1 (0.66) KDM4ERAB9ASMN1; SMN2MAPK1NOTUM
SCHEMBL24534769 0.74 KDM4E (0.36) KDM4ENPC1RAB9ASMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220193041-A1 NOVEL COMPOUND AND METHOD FOR PREVENTING OR TREATING OF RESPIRATORY DISEASES COMPRISING THE SAME AS AN ACTIVE INGREDIENT Yonsei University, University - Industry Foundation (UIF) (KR) 2022-06-23 US disclosed
EP-3949963-A1 NOVEL COMPOUND AND COMPOSITION FOR PREVENTION OR TREATMENT OF RESPIRATORY DISEASES COMPRISING SAME AS ACTIVE INGREDIENT Yonsei University, University-Industry Foundation(UIF). (KR) 2022-02-09 EP disclosed
WO-2020204602-A1 NOVEL COMPOUND AND COMPOSITION FOR PREVENTION OR TREATMENT OF RESPIRATORY DISEASES COMPRISING SAME AS ACTIVE INGREDIENT 연세대학교 산학협력단 2020-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220193041-A1 NOVEL COMPOUND AND METHOD FOR PREVENTING OR TREATING OF RESPIRATORY DISEASES COMPRISING THE SAME AS AN ACTIVE INGREDIENT EPX, CFTR, MPO KDM4E 4043/4885NPC1 47/4885RAB9A 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.